China's Xuanzhu hits fresh high on progress of breast cancer treatment

Xuanzhu Biopharmaceutical

22/10/2025 04:57

** Shares of Xuanzhu Biopharmaceutical 2575.HK soar as much as 26.8% to HK$57.7, a new high after debuting in Hong Kong on October 15

** Xuanzhu says the interim analysis results of Phase III clinical study to evaluate the efficacy and safety of its Bireociclib treatment in advanced breast cancer were presented at the European Society for Medical Oncology in Germany on October 20

** Says Bireociclib regimen can reduce risk of disease progression, and common adverse events such as diarrhea and neutropenia can be effectively managed through dose adjustment, with overall controllable safety

** Stock up 374% since debut on October 15; YTD, Hang Seng Biotech Index .HSBIO up 82%

 (Reporting by Donny Kwok)

 ((donny.kwok@thomsonreuters.com))